Show simple item record

dc.contributor.authorThatcher, Nick
dc.contributor.authorLee, Siow Ming
dc.contributor.authorWoll, Penella J
dc.contributor.authorMiddleton, Mark R
dc.contributor.authorAnderson, Heather
dc.contributor.authorBurt, Paul A
dc.contributor.authorStout, Ronald
dc.date.accessioned2010-02-09T16:48:28Z
dc.date.available2010-02-09T16:48:28Z
dc.date.issued1998-04
dc.identifier.citationDose intensity in small cell lung cancer. 1998, 25 (2 Suppl 4):12-8; discussion 45-8 Semin. Oncol.en
dc.identifier.issn0093-7754
dc.identifier.pmid9578057
dc.identifier.urihttp://hdl.handle.net/10541/91675
dc.description.abstractEvidence from preclinical models and from clinical trials describing the importance of dose intensity in securing a better treatment outcome is reviewed. Recent randomized trials have shown statistically significant survival benefits with higher-dose, accelerated chemotherapy regimens with and without granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. The novel use of peripheral blood progenitor cells contained in whole blood autotransfusions, which allow a marked increase in dose intensity of an ifosfamide/carboplatin/etoposide regimen, could provide a much easier method of delivering dose-intensive chemotherapy than previously available.
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectHaematopoietic Stem Cell Transplantationen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshClinical Trials as Topic
dc.subject.meshGranulocyte Colony-Stimulating Factor
dc.subject.meshGranulocyte-Macrophage Colony-Stimulating Factor
dc.subject.meshHematopoietic Stem Cell Transplantation
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.titleDose intensity in small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalSeminars in Oncologyen
html.description.abstractEvidence from preclinical models and from clinical trials describing the importance of dose intensity in securing a better treatment outcome is reviewed. Recent randomized trials have shown statistically significant survival benefits with higher-dose, accelerated chemotherapy regimens with and without granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. The novel use of peripheral blood progenitor cells contained in whole blood autotransfusions, which allow a marked increase in dose intensity of an ifosfamide/carboplatin/etoposide regimen, could provide a much easier method of delivering dose-intensive chemotherapy than previously available.


This item appears in the following Collection(s)

Show simple item record